Which has better earnings and valuation, RCKT or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is RCKT or MLTX more profitable?

Rocket Pharmaceuticals' return on equity of -69.61% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rocket Pharmaceuticals N/A -69.61% -58.63% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Do analysts recommend NNNN or RCKT?

Rocket Pharmaceuticals has a consensus price target of $8.71, indicating a potential upside of 173.18%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rocket Pharmaceuticals 3 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.30

Which has better earnings and valuation, NNNN or RCKT?

Anbio Biotechnology has higher revenue and earnings than Rocket Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 164.74 $6.40M N/A N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$1.87 N/A

Is NNNN or RCKT more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Is AKTS or RCKT more profitable?

Aktis Oncology's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Rocket Pharmaceuticals N/A -69.61% -58.63%

Rocket Pharmaceuticals (RCKT) Competitors

$3.19 -0.09 (-2.74%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.20 +0.00 (+0.16%)

As of 07/24/2026 07:34 PM Eastern

Compare

RCKT vs. MLTX, NNNN, PAHC, AKTS, and XNCR

Should you buy Rocket Pharmaceuticals stock or one of its competitors? MarketBeat compares Rocket Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), Anbio Biotechnology (NNNN), Phibro Animal Health (PAHC), Aktis Oncology (AKTS), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry.

How does Rocket Pharmaceuticals compare to MoonLake Immunotherapeutics?

Rocket Pharmaceuticals (NASDAQ:RCKT) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rocket Pharmaceuticals' return on equity of -69.61% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

In the previous week, MoonLake Immunotherapeutics had 14 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 1 mentions for Rocket Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.74 beat Rocket Pharmaceuticals' score of 0.53 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Rocket Pharmaceuticals	Positive
MoonLake Immunotherapeutics	Positive

Rocket Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Rocket Pharmaceuticals presently has a consensus target price of $8.71, indicating a potential upside of 173.18%. MoonLake Immunotherapeutics has a consensus target price of $24.21, indicating a potential upside of 27.31%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Summary

Rocket Pharmaceuticals beats MoonLake Immunotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

Anbio Biotechnology has higher revenue and earnings than Rocket Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	164.74	$6.40M	N/A	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Anbio Biotechnology's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Anbio Biotechnology has a beta of 5.15, meaning that its share price is 415% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

In the previous week, Anbio Biotechnology had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 2 mentions for Anbio Biotechnology and 1 mentions for Rocket Pharmaceuticals. Anbio Biotechnology's average media sentiment score of 1.43 beat Rocket Pharmaceuticals' score of 0.53 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Rocket Pharmaceuticals	Positive

Rocket Pharmaceuticals has a consensus price target of $8.71, indicating a potential upside of 173.18%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Summary

Anbio Biotechnology beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Rocket Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

Phibro Animal Health presently has a consensus price target of $42.50, suggesting a potential upside of 24.89%. Rocket Pharmaceuticals has a consensus price target of $8.71, suggesting a potential upside of 173.18%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Phibro Animal Health had 3 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 4 mentions for Phibro Animal Health and 1 mentions for Rocket Pharmaceuticals. Phibro Animal Health's average media sentiment score of 1.59 beat Rocket Pharmaceuticals' score of 0.53 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Phibro Animal Health	Very Positive
Rocket Pharmaceuticals	Positive

Phibro Animal Health has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.06	$48.26M	$2.33	14.61
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Phibro Animal Health beats Rocket Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aktis Oncology presently has a consensus target price of $34.60, indicating a potential upside of 44.83%. Rocket Pharmaceuticals has a consensus target price of $8.71, indicating a potential upside of 173.18%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Aktis Oncology's return on equity of 0.00% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%

In the previous week, Aktis Oncology had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for Aktis Oncology and 1 mentions for Rocket Pharmaceuticals. Aktis Oncology's average media sentiment score of 1.06 beat Rocket Pharmaceuticals' score of 0.53 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Aktis Oncology	Positive
Rocket Pharmaceuticals	Positive

Aktis Oncology has higher revenue and earnings than Rocket Pharmaceuticals. Aktis Oncology is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A

Summary

Aktis Oncology beats Rocket Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Xencor?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Xencor has higher revenue and earnings than Rocket Pharmaceuticals. Xencor is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Xencor	$125.58M	11.48	-$91.92M	-$2.29	N/A

Rocket Pharmaceuticals presently has a consensus target price of $8.71, indicating a potential upside of 173.18%. Xencor has a consensus target price of $24.25, indicating a potential upside of 24.74%. Given Rocket Pharmaceuticals' higher probable upside, equities research analysts plainly believe Rocket Pharmaceuticals is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Xencor	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Rocket Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, Xencor has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Xencor's return on equity of -28.77% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Xencor	-177.10%	-28.77%	-20.52%

In the previous week, Xencor had 4 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 5 mentions for Xencor and 1 mentions for Rocket Pharmaceuticals. Xencor's average media sentiment score of 0.53 beat Rocket Pharmaceuticals' score of 0.53 indicating that Xencor is being referred to more favorably in the news media.

Company	Overall Sentiment
Rocket Pharmaceuticals	Positive
Xencor	Positive

Summary

Xencor beats Rocket Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$358.15M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-1.71	21.11	27.00	23.71
Price / Sales	N/A	164.10	492.66	73.79
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.25	7.88	10.28	6.07
Net Income	-$223.12M	$23.81M	$3.60B	$331.84M
7 Day Performance	-7.27%	-3.79%	-1.25%	-1.53%
1 Month Performance	-1.54%	-2.59%	-0.35%	-2.46%
1 Year Performance	1.59%	32.85%	18.41%	13.66%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.7327 of 5 stars	$3.19 -2.7%	$8.71 +173.2%	-0.6%	$358.15M	N/A	N/A	240
MLTX MoonLake Immunotherapeutics	3.2022 of 5 stars	$19.05 -3.2%	$24.21 +27.1%	-65.4%	$1.45B	N/A	N/A	2	Analyst Revision
NNNN Anbio Biotechnology	1.4117 of 5 stars	$9.52 +0.3%	N/A	N/A	$1.37B	$8.65M	N/A	27	Positive News Short Interest Decrease
PAHC Phibro Animal Health	4.8465 of 5 stars	$33.05 -0.8%	$42.50 +28.6%	+15.6%	$1.35B	$1.30B	14.18	2,475	Positive News
AKTS Aktis Oncology	2.3347 of 5 stars	$23.96 -3.7%	$34.60 +44.4%	N/A	$1.33B	$6.50M	N/A	76	News Coverage Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MLTX, NNNN, PAHC, AKTS, and XNCR

How does Rocket Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does Rocket Pharmaceuticals compare to Anbio Biotechnology?

Summary

How does Rocket Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Rocket Pharmaceuticals compare to Aktis Oncology?

Summary

How does Rocket Pharmaceuticals compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. MLTX, NNNN, PAHC, AKTS, and XNCR

How does Rocket Pharmaceuticals compare to MoonLake Immunotherapeutics?

Do insiders and institutionals have more ownership in RCKT or MLTX?

Is RCKT or MLTX more profitable?

Which has better earnings and valuation, RCKT or MLTX?

Does the media favor RCKT or MLTX?

Which has more volatility & risk, RCKT or MLTX?

Do analysts recommend RCKT or MLTX?

Summary

How does Rocket Pharmaceuticals compare to Anbio Biotechnology?

Which has better earnings and valuation, NNNN or RCKT?

Is NNNN or RCKT more profitable?

Do insiders & institutionals believe in NNNN or RCKT?

Which has more volatility and risk, NNNN or RCKT?

Does the media prefer NNNN or RCKT?

Do analysts recommend NNNN or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Phibro Animal Health?

Which has more volatility & risk, PAHC or RCKT?

Is PAHC or RCKT more profitable?

Do analysts recommend PAHC or RCKT?

Does the media prefer PAHC or RCKT?

Which has higher earnings and valuation, PAHC or RCKT?

Do institutionals & insiders hold more shares of PAHC or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Aktis Oncology?

Do insiders & institutionals have more ownership in AKTS or RCKT?

Do analysts recommend AKTS or RCKT?

Is AKTS or RCKT more profitable?

Does the media refer more to AKTS or RCKT?

Which has higher earnings and valuation, AKTS or RCKT?

Summary

How does Rocket Pharmaceuticals compare to Xencor?

Which has better valuation and earnings, RCKT or XNCR?

Do analysts prefer RCKT or XNCR?

Which has more risk & volatility, RCKT or XNCR?

Do insiders and institutionals believe in RCKT or XNCR?

Is RCKT or XNCR more profitable?

Does the media prefer RCKT or XNCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools